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Perinatal hypoxic-ischemic brain injury, as a result of chronic, subacute, and acute insults, represents the pathological consequence
of fetal distress and birth or perinatal asphyxia, that is, “nonreassuring fetal status.” Hypoxic-ischemic injury (HII) is typically
characterized by an early phase of damage, followed by a delayed inflammatory local response, in an apoptosis-necrosis
continuum. In the early phase, the cytotoxic edema and eventual acute lysis take place; with reperfusion, additional damage
should be assigned to excitotoxicity and oxidative stress. Finally, a later phase involves all the inflammatory activity and long-
term neural tissue repairing and remodeling. In this model mechanism, loss of mitochondrial function is supposed to be the
hallmark of secondary injury progression, and autophagy which is lysosome-mediated play a role in enhancing brain injury.
Early-induced molecules driven by hypoxia, as chaperonins HSPs and ORP150, besides common markers for inflammatory
responses, have predictive value in timing the onset of neonatal HII; on the other hand, clinical biomarkers for HII diagnosis, as
CK-BB, LDH, S-100beta, and NSE, could be useful to predict outcomes.
1. Introduction
Defining the field of interest of this review is not that easy as
it could seem. Dealing with perinatal hypoxic-ischemic brain
injury, in fact, it is possible to find in literature quite different
definitions and diagnostic categories. When we use the term
of hypoxic-ischemic injury (HII) to the developing brain, we
are referring to what already happened to a baby we probably
have followed from at least labor and delivery until the onset
of a patent encephalopathy. Otherwise, clinicians and
especially gynecologists and obstetrics among them facing a
pregnant woman with trouble in the meanwhile of delivery
would generally talk about fetal distress and birth or perinatal
asphyxia [1]. Furthermore, in the last few years, they prefer to
talk about “nonreassuring fetal status” instead of fetal distress
as it is hard to establish the effective fetal conditions before
evaluating the baby at birth and along his first days of life
[2–4]. HII represents the pathological consequence of the
aforementioned conditions. It is hard to establish an exact
correspondence between the two because often no neonatal
trouble follows a clearly established fetal distress and a
difficult labor or delivery [5].
These pathological conditions can be divided into 3 main
subtypes depending on the timing of onset. We should differ-
entiate, then, among chronic, subacute, and acute insults.
The first is usually easy to recognize as there is an evident
perturbation of normal intrauterine development during
the second or early third trimester of gestation; usually, there
are clear correlates at placental pathology, too [6]. These
cases most of the times come to an intrauterine fetal death
or a stillbirth; even if labor and delivery are prolonged or dif-
ficult, this fact represents a consequence rather than a cause
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of the newborn pathological development. Otherwise, sub-
acute and acute forms happen in the perinatal interval which
could start even 48 hours before birth; they are not easy to
distinguish from each other as there is a lack of clinical and
instrumental parameters for clearly identifying a prenatal
injury. Moreover, it should be taken into account that a
subacute condition may evolve into an acute one; the main
difference, in fact, is the quickness which is more evident in
the acute form and leads to a faster evolution from the initial
insult to the lesions and clinical correlates.
Outcomes of subacute and acute fetal distress range from
intrauterine death, stillbirth, and neonatal death to neonatal
encephalopathy. This is a general term preferred to the more
specific hypoxic-ischemic encephalopathy (HIE) when it is
still undetermined whether the cause has been a perinatal
HII or not [7]. By the way, a universally agreed definition
of both these terms is still lacking [8].
The problem we want to stress with the present review
is that in the real setting, the abovementioned conditions
overlap so that it is hard to assess an etiological diagnosis
to a given case. Even chronic fetal injury may pass unno-
ticed during pregnancy, and its pathological correlates may
be confused with subacute and acute events. Another fac-
tor which complicates this picture is the gestational age of
the fetus because it is well known that prematurity by
itself leads to additional risks and vulnerability in the early
postpartum period.
From the clinical point of view, it could seem not that
important to address every consequence to the specific cause
and relative onset, but it is paramount in the forensic and
medicolegal setting where the judgment about the medical
liability should be set upon the ascertainment of the causal
relationships, both in civil and penal trials.
1.1. Epidemiology. In the last few years, intrapartum-related
neonatal deaths have been assessed at the fifth place in the
most common causes of death chart among children less
than 5 years old [9]. This makes a worldwide estimate of
more than 800,000 deaths per year. Considering all perinatal
fatal outcomes, these cases represent about a quarter of total
3 million deaths and almost half of 2.6 million third trimester
stillbirths [10].
Dealing with different reports and meta-analysis regard-
ing full-term births [11], perinatal asphyxia has an incidence
of 1–6 per 1000 live births with a mortality rate up to 20%.
About one-half of survivors suffer from neuropsychological
sequelae of immediate or delayed onset [12] while 25% show
major neurological impairments.
If considering neonatal encephalopathy, it is estimated
that from 1 to 3 per 1000 live births, a half of them were
accountable for a hypoxic-ischemic causation [13].
In these data, there are significative discrepancies
between high-income countries, developing, and low-
income ones; in the first ones, survival rate is definitely better
while the latter ones show an incidence of neonatal encepha-
lopathy lower than expected. This is obviously due to the
underestimation related to the shorter overall survival time
which does not allow encephalopathy to take place. More-
over, it can be estimated as a kind of evidence for intrapartum
hypoxia-ischemia in the 30% or 60% of cases, respectively, in
developed and developing countries.
1.2. Role of Perinatal Hypoxia. In the case of chronic intra-
uterine insult, it is possible to identify clear etiopathogenic
factors, such as placental insufficiency, chorioamnionitis,
genetic anomalies, or toxic exposure. Otherwise, when brain
injury occurs in an acute or subacute manner, lots of different
factors may have played a role.
Birth asphyxia has been defined as “a condition of
impaired blood gas exchange, leading, if it persists, to pro-
gressive hypoxemia and hypercapnia.” Unfortunately, this
statement does not provide any precise clinical parameter
to affirm such a diagnosis in a given case or in a study cohort.
Main clinical events associated with perinatal asphyxia
can be summarized as the following: placental abruption,
meconium staining, labor dystocia (abnormal uterine con-
tractions, obstructed labor), cord knots, cord prolapse, and
uterine rupture. A significant problem is that sometimes
clinicians just ascertain “the failure of the neonate to success-
fully begin breathing,” not surprisingly the WHO in its
“practical guide to newborn resuscitation” preferred to
choose the latter as the only definition provided [14]. Briefly,
we have to face a complex scenario where causes and conse-
quences, as clinical correlates of perinatal asphyxia, confuse
with each other.
In some recently published papers, the authors seem to
treat “birth asphyxia” and “perinatal hypoxia-ischemia” as
perfect synonyms [15], but this cannot simplify the problem
by itself. As a matter of fact, although the most objective
assessment of the presence of intrapartum hypoxia-
ischemia is metabolic acidosis in umbilical arterial blood at
the time of birth [16], not all the authors refer to the same
cut-off values or strictly measure these parameters in their
studies. Basic controversies exist also regarding the definition
of neonatal encephalopathy (NE) and hypoxic-ischemic
encephalopathy (HIE) [17].
All these facts explain partially why authors disagree so
much about incidence of intrapartum causes in neonatal
brain injury: some of them affirm a minor role [18–20], while
others still consider them surely predominant [21, 22], at
least whenmajor congenital malformation and chromosomal
disorders are excluded [23, 24].
Another reason for disagreement is that nowadays, it is
well established that cerebral palsy in children is linked to
an intrapartum event only in the 10–20% of cases [25]; it is
necessary to keep in mind that often cerebral palsy does not
have any pathological presentation in the first weeks of life.
Indeed, encephalopathic babies at birth and children affected
by cerebral palsy are not two identical groups.
1.3. The Medicolegal Matter of Interest. The reported epide-
miological data underline that HIE is not only a public health
concern. In the last two decades, medicolegal claims arisen
from perinatal brain injury have been always growing.
Recently birth-related events have been estimated to account
for about a half of the cases dealt with by the National Health
Service Litigation Authority in the UK. If it is well known as
medical malpractice litigation in the developed world that
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has reached huge proportions, an important place should be
assigned to neonatal brain injury compensation. According
to the report of a consortium of insurance companies in the
USA, this kind of damage is at the top of the list of pediatric
claims (from 1985 to 2008) with an average indemnity of
about 500,000 dollars [26].
The present system, especially in the civil courts, is out-
come-based, and this fact consists of a guilt prejudice upon
physicians. This depends notably on the lack of clear and
univocal criteria but also on the unavailability of those proofs
and tests which allow reaching the causal correlation on the
basis of evidence. This uncertainty results in unpredictable
judicial trials with similar cases often judged in the opposite
way: conviction and discharge verdicts, thus, are based some-
times on nonobjective medicolegal and forensic evaluation,
especially when some elements are ignored or neglected.
Medicolegal evaluation is certainly much more oriented
when dealing with a fatal case so that a judicial autopsy has
been disposed. In literature, it is largely represented how full
postmortem examination, including a complete autopsy,
may provide elements of paramount importance from a
quantitative as long as a qualitative point of view [27, 28].
Nevertheless, autopsy alone cannot provide all the solutions
to the correct decision.
Timing of injury is definitely the key element in the legal
arena as the defense will always try to demonstrate that injury
occurred in a different moment rather than the strict intra-
partum period; the confutation of causality relationship, in
fact, will be overwhelming on claims about eventually debat-
able physicians’misconduct [29]. By the way, when cases are
particularly delicate, especially in civil courts, it is necessary
to finely distinguish concomitant causes between human
and natural ones [30], then natural causes between prevent-
able and unpreventable ones; at the same time, an explication
of the relative weight of each of them should be given. Easy to
see how the timing of injury and consequent impairment is
an essential question, not limited to the simple assessment
whether it is an antepartum or intrapartum onset but regard-
ing the promptness of procedures performed by all the health
assistance personnel too.
2. Pathobiology of Hypoxic-Ischemic
Brain Injury
2.1. Pathophysiology. As it is not easy to identify the exact
etiological factor related to HII to the neonatal brain, in the
same manner, there is still uncertainty about all processes
leading to the well-described neuropathological features
reviewed below. The first event in the pathophysiology of this
condition is the instauration of central fetal hypoxemia, since
the impairment in feto-placental hemodynamics and blood
gas exchange is established [31]. Quickly hypoxia is followed
by ischemia; this is the reason why we talk about a “hypoxic-
ischemic” injury and both components should always be
considered together in the subsequent lesions. Thus, in
addition to reduced oxygen, also lessening of glucose supply
and increasing of carbon dioxide are involved in the brain
damage leading to the complex metabolic impairment which
is characteristic of HII [32].
It has been demonstrated that ischemia is induced by the
combination of myocardial dysfunctions and the loss of cere-
bral self-regulation of blood flow. Intracranial hypotension
and hypoperfusion worsen tissue anoxia and reduce meta-
bolic substrate supply. By the way, the critical characteristic
of HII in the perinatal period is the intrinsic vulnerability
of the immature brain [33, 34]. This depends on the high
energetic need of neurons, specific interneuronal connections
[35], and immaturity of oligodendrocyte lineage [36, 37].
The early phase of damage involves vascular mechanisms
too. From one side, vasoconstriction takes place and, above
all, hypotension may lead to vascular collapse; from the
other, the endothelial damage at the microcirculation causes
a marked opening of the blood-brain barrier. When the
strictly selective permeability of this district is compromised,
toxic agents are licensed to pass and worsen brain damage.
The early phase of damage, which lasts for the first 24–48
hours from the initial insult, is followed by a delayed injury
[38]. This is mainly driven by the inflammatory local
response [39, 40]. Focusing on the further development of
the central nervous system, the perinatal HII can be inter-
preted as the initial noxa of a subsequent altered neural
migration and differentiation due to hypoxic-induced angio-
genesis and vascular activation [41, 42].
Finally, when considering the complex pathophysiology
of HIE, one should remember that general conditions of
the newborn, which usually complicate perinatal asphyxia
(glucose, electrolytes, and ammonium imbalance), may play
a role in worsening brain damage and precipitating mid
and long-term prognosis [43].
2.2. Molecular Pathways. Neurons affected by a hypoxic-
ischemic insult undergo usual effects as seen in general
cytopathology. The failure of oxidative energetic metabo-
lism in providing a sufficient level of ATP determines the loss
of intracellular homeostasis; the Na+/K+ pump function
ceases and the consequent osmotic and electrochemical
gradient produces the cell swelling. Depending on the inten-
sity and prolongation of the insult, this process can reach an
acute cell lysis.
By the way, in most cases of brain injury, there is a
network of cross-talking cellular processes that results in
the combination of the 2 main cellular deaths: necrosis
and apoptosis. Apoptosis plays an important role in brain
development as immature cells are likely more prone to
apoptosis even in physiological conditions [44]. When a
hypoxic-ischemic injury occurs, apoptosis and necrosis
overlap so much that nowadays it is common to talk
about an apoptosis-necrosis continuum in a given injured
brain area [45, 46].
This fact can be explained describing a typical response to
HII in the neural tissue which actually is common also to
other kinds of noxa; it is known as “excitotoxicity” [47] and
shows how the accumulation of excitatory amino acids
(EEAs) in the extracellular medium promotes neuronal death
[48]. The mechanisms initially derived by in vitro experi-
ments and confirmed by in vivo models are like a vicious
cycle in which the central role is held by NMDA receptors
[49]. These, in fact, are activated by extracellular glutamate
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(the main excitatory neurotransmitter of CNS) and drive a
self-perpetuating influx of Ca2+ involving the Na+ channels
[50]. This triggers all the enzymatic Ca-dependent cascades
which lead both to apoptosis and necrosis [51].
It could be that the pivotal role in determining a more
oriented progression towards necrosis rather than apoptosis
is played by the specific mitochondrial dysfunction [52]. This
damage is being deeply investigated in the field of brain
injury because the loss of mitochondrial function is supposed
to be the hallmark of secondary injury progression [53].
All these mechanisms have been reviewed recently [54].
It is well depicted that there are at least three chronologically
distinct stages: in the early phase, the cytotoxic edema and
eventual acute lysis take place; with reperfusion, additional
damage should be assigned to excitotoxicity and oxidative
stress; finally, the later phase involves all the inflammatory
activity and long-term neural tissue repairing and remodel-
ing. This confirms that time-dependent representation of
neuropathological findings, as in more details below, has a
biological and molecular basis because only a few neurons
die during the actual ischemic event while a delayed cell
death continues along a latent phase.
Nevertheless, this chronological distribution alone can-
not provide a reliable paradigm to answer the question if a
given HII started during labor and delivery or it is linked
to a previous insult.
2.3. Novel Insights into Injury Mechanisms. Besides apo-
ptosis and necrosis, a more recently discovered kind of
cellular death is being investigated in relation to neonatal
brain injury, that is, autophagy. Autophagy is a controlled
lysosome-mediated cellular function to eliminate damaged
or aged organelles and to maintain cell survival under
multiple stresses; unfortunately, under certain conditions,
this homeostatic process results in cell death [55]. Histori-
cally, it seemed at least ambiguous if this peculiar adaptative
response could play an effective protective function in the
field of brain HII. In literature, it was possible to find
opposite conclusions to this crucial question: some authors,
applying on experimental pharmacological tests, argued
that autophagy actively contrasted lesion progression,
limiting the extension of necrosis [56]; at the opposite
side, some authors, using knockout rats, concluded that this
process was deleterious [57].
We believe that the recent research by Ginet et al. [58]
provides a univocal and reliable answer. They combined an
in vitro and in vivo approach in the same experiment and
showed clearly from both sides the pathological role of
autophagy while a hypoxic-ischemic insult acts: autophagy
adds itself to the apoptosis-necrosis continuum and enhances
brain injury. It is remarkable how they obtained in vivo
proofs implementing the technique of inducing specific gene
downregulation with targeted lentiviral vectors.
With similar experimental strategies, other molecules
have been linked to central mechanisms in this kind of neu-
ronal lesions. Recently, the potential role of the oxidative
product hydrogen sulfide (H2S) has been highlighted [59]:
according to the work by Lechpammer et al. [60], it connects
the injury-related activation of the enzyme cystathionine-
beta-synthase with the mTOR-dependent pathway. The
authors, in fact, found a neuroprotective potential with rapa-
mycin, the well-known prototypical inhibitor of mTOR.
Fascinating insights into HII pathogenesis come from
epigenetic studies, even if they were originally set for cancer
and tumor cells [61]. Researchers in this field started from a
deep investigation of gene expression in the developing brain,
focusing on the checkpoints in cellular and tissue differentia-
tion. Then they looked for molecular links between already
known injury triggers and intermediate or late processes
[62]. The epigenetic dysregulation leading to the main cellu-
lar enzymatic activity involved in all mechanisms seen above
is being depicted [63]. Epigenetics can explain also which
way specific conditions interact and worsen HII. It happens,
for example, when fetal antenatal stress and consequent
epigenetic repression of GR (glucocorticoid receptor) brain
expression abrogate the neuroprotective action of corticoste-
roids [64, 65]. According to the state of art among miRNA,
which are the most investigated protein expression modula-
tors, the ones that have been related to hypoxic-ischemic
brain injury are miRNA 210 [66], a well-known hypoxia
upregulated mediator [67], miRNA 128 [68], and, above
all, miRNA 9.
All these experimental evidences are still far away to be
applicable in the clinical setting; they are insufficient to clar-
ify all the aspects of pathobiology in HII of the neonatal brain
too. Nevertheless, we believe that scrutinizing and mapping
also in a time-sensitive manner, the spectrum of miRNA
expression in damaged and perilesional tissues could provide
very precise diagnostic tools if matched with advanced
microscopy and molecular biology.
3. Assessment of Timing of the Onset
3.1. Clinical Approach.About clinical presentation of HIE, no
certain time relationship can be established with timing of
injury. It has been observed that latency for first observable
seizures can range from minutes to a few days from birth
even when a clear asphyxial event occurred [69]. These
ranges might preclude assignment of an injury to the time
of labor [70].
Some authors reviewed the literature for identifying a
reliable timer, and they assumed that persistent fetal brady-
cardia could work; by the way, it was only obtained from pri-
mate experimental models which have been largely criticized
because of poor similarity to the real clinical setting. Some
other parameters have been tested such as lymphocytosis
and thrombocytopenia in the neonate blood by retrospective
medical chart review. Conclusions admitted that even if
lymphocytosis may be reliable, it refers only to a strict time
window between initial insult and blood sampling; further-
more, it is applicable only in definite conditions and lots of
confounding factors exist.
Another problem is the late-referral pregnant women
with labor troubles; if there is no previous recent clinical
observation, even an impressive event like fetal movement,
stopping may become not valuable.
Anyway in the clinical setting defining the time of the
onset is not of great importance in itself as neonatologists
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are more interested in quickly assigning a prognosis and send
the newborn to the most proper therapeutic strategy. Nowa-
days, in fact, some new resources are available in this field
[71] and others are being developed [72], like the intravenous
administration of autologous cord blood cells [73] or an
erythropoietin support [74]. However, the most important
one, the medical hypothermia [75, 76], is administered only
in a few centers. From the other hand, certain advanced
drugs are potentially dangerous and babies who will likely
not beneficiate should be exempted from the risk.
3.2. Neuropathology. Neuropathological findings related to
neonatal encephalopathies and brain damage have been
reviewed more than once in literature. We suggest referring
to a few of these monographs for a more detailed description
of each pattern reported below [77–79]. Our aim is to focus
on controversies dealing with assessing a definite etiological
diagnosis and establishing the timing of onset.
This field of pediatric neuropathology, in fact, is char-
acterized by a huge variety of aspects deriving from the
complex biology of neurological damage in the developing
brains. Ethical issues which reasonably limit research
access to death cases join the obvious unavailability of human
samples coming from patients who are still alive. Lots of
evidence, then, come from experimental models of mamma-
lian neonates in which injuries are caused almost ever by total
occlusion of main cerebral arteries. One of the most referred
procedure is the Rice-Vannucci which consists of unilateral
common carotid artery ligation, followed by hypoxic envi-
ronment exposure (pO2=8%) [80, 81]. Usually, such an
experiment produces an “all or none” phenomenon which
is clearly limiting comparing with the number of combina-
tions of different lesions observed in real human cases.
Classical patterns have been divided into subtypes and
kind of classes of frequency dealing with the gestational
age of the newborn. However, we do not consider this
classification useful enough for our principal intent as we
are interested the most in assigning lesions to a precise
chronological relationship with labor and birth. Before
summarizing these aspects, it is important to remind that lots
of factors besides timing of the onset contribute to the
specific pathological picture. First of all, it is mandatory
to consider the duration of the insult, which determines
greatly but not entirely the intensity of the insult itself; the
comorbidities, again, both from fetal and maternal side; the
effective fetal growth with respect to gestational age; and
the topographic distribution when mechanical forces are
supposed to have been involved in the injury.
Considering all these facts in literature, there is a con-
sensus in recognizing at least 3 stages in the pathological
progression of developing brain damage [82]. In an
“acute” phase (restricted to a time window of 8–24 hours),
aspects of cellular death prevail, with hypereosinophilic
neurons and nuclear pyknosis in the gray matter, while
coagulative necrosis and classical axonal spheroids in the
white matter. The “subacute” inflammatory phase is consid-
ered starting at least 72 hours after the first onset and is
characterized by macrophage infiltration or small collections
and “gliosis” (glia activation), which means microglial
nodules surrounding dead neurons and mineralization of
cell residues (gray matter), and reactive astrocytes (both
gray and white).
In this progression, someone else [83] individuated
another time window in the acute phase with appearance of
neuronal karyorrhexis, which would occur between 24 and
48 hours but this is not elsewhere accepted in literature.
What is undoubted, instead, is the label of chronic sequelae
(weeks-months) for gross pathological appearances like
cavitation or coarse spongiosis of the cortex or periventricu-
lar cysts and glial scars. A well-described late pattern is the
“marbled state” of basal ganglia, which is supposed to be
the effect of an altered process of reactive long-term hyper-
myelinization of nonaxonal fibers. The counterpart in the
white matter could be recognized in the so-called “periventri-
cular leukomalacia” (PVL), which consists of 2 major
components: the results of focal necrosis of deeper white
matter (cysts, scars, but most of all ventriculomegaly) and
more diffuse injury with marked microgliosis and astrocyto-
sis. This aspect has been elsewhere depicted as DWMG
(diffuse white matter gliosis), characterized by hypertrophic
astrocytes, capillary cell proliferation, and perivascular
“globules” eventually mineralized [84].
The chronological progression proposed is clearly depen-
dent on survival interval from injury and subsequent in vivo
modifications. The derived assessment of the timing of the
onset is based on a retrospective (a fortiori) measurement,
with no intrinsic relationship with labor- or delivery- associ-
ated events. Another problem is that has been well demon-
strated how the correspondent acute phase of a chronic
basal ganglia and thalami-altered morphology can result just
in subtle findings of apoptosis and/or necrosis which may be
easily overlooked histopathologically.
Furthermore, the utilization of the aforementioned
parameters implicates several limitations: the time windows
are too long, being able to include both antepartum and post-
partum events; there is a time “hollow” between 24 and 72
hours with no specific findings; and it is of no usefulness after
a few days from delivery.
To overtake these limitations, we would need better
knowledge about correlation between the kind of intrapar-
tum insult or risk factor-associated (see above) and
topographical or qualitative representation of lesions and
respective pathological sequelae. By now, we can just con-
sider that some disorders of gyration with observable
cytoarchitectural disorganization refer typically to a certain
gestational interval; similarly, we know that PVL, when
already established at birth, is likely related to an insult
occurring between the 24th and the 34th gestational week.
These correlations are consistent with the well-known princi-
ple that lesional pattern in the developing brain is determined
by specific neuronal susceptibility to hypoxic-ischemic injury
related to structure and morphogenesis.
Another aspect, which deserves analysis and further
research, is the effect of injury timing in determining the
particular combination of grey and white matter. We are
talking about the possible association with PVL of damage
localized in the grey matter, at the subplate neurons, cortex,
basal ganglia, and thalami [85].
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3.3. Neuroimaging. Neuroimaging is gaining more and
more importance for neonatologists as it allows searching
for a pathological counterpart in the clinical setting. Almost
all, both in research and real world, deal with MRI, as CT
scans need dangerous ionizing radiations and transcranial
ultrasound exams have poor sensitivity [86]. Moreover,
technical advances and knowledge exploitation in perform-
ing all possible sequences and parameters have improved its
diagnostic usefulness and potential application in timing
the onset of injury.
Pathological patterns have been classified traditionally
in 4 types on a topographical involvement basis: deeper
structures, cortex, periventricular white matter, and mixed
[87]. It is clear that images at MRI are not comparable
with neuropathological observable patterns in term of resolu-
tion and detail characterization; from the other side, they
share the same variability depending on not only intensity
and prolongation of hypoxia-ischemia but most of all on
developmental stage of neonatal brain and on time span from
injury to exam [88]. First, we should notice that, once
again, this lag time is determined by the timing of clinical
presentation, rather than effective onset of brain injury.
Then, it is controversial in literature when should MRI
be performed on neonates when there is a clinical question
about eventual brain lesions.
Besides mere recognition of abnormal patterns and
support to definite diagnosis, in fact, clinicians show interest
in neuroimaging as it can lead to an earlier assessment of dis-
ease and even prognosis [89, 90]. Dealing with the first issue
in someone’s opinion, the hypoxic injury pattern on MRI is
not diagnostic for 7–14 days [91], as perinatal brain lesions
are at their most visually obvious state between 1 and 2 weeks
from delivery [92]. This fact could be an important limitation
in those cases characterized by a shorter survival interval
[93]. At the same time, the finding of diffusion restriction
at DWI-MR is accounted for enabling early detection of
injury, even on the first day [94]; this is the reason why some
authors assert that this kind of sequence imaging is optimally
obtained between 3 and 5 days from delivery [95]. In any
case, diffusion-weighted parameters still lack sensitivity and
may lead to underestimate the extent of lesions [96, 97],
especially when deep gray matter is involved. One more
method implemented to anticipate HIE detection at MRI is
to combine conventional imaging acquisition and proton
MR spectroscopy for anaerobic metabolism markers
(increased lactate and decreased N-acetyl-aspartate) [98].
Anyway, not all the authors agree about its feasibility because
of poor specificity. Lastly, diffusion tensor imaging (DTI)
modifications are being mapped in relation to neonatal brain
HII [99, 100] and long-term outcomes [101].
About prognosis, a specific MRI scoring system was
proposed already in the 90s, but it consisted of a weighted
analysis of topographically different signal abnormalities to
find a correlation with neuromotor impairment during the
first 12 months of life [102]. Rather than being a real prog-
nostic tool, it helps to the interpretation of subtle findings
when clear pathological patterns are not evident. This is the
same for the discussed “prognostic” value of signal changes
in the posterior limb of the internal capsule (PLIC) [103].
If uncertainty exists about effective time specificity of sig-
nal changes at each MRI acquisition sequence, neuroimaging
exams obtained in the first weeks of life are believed effective
in excluding an ancient antepartum process [70]. Usually, in
fact, they are used in clinical studies as criteria suggestive of
antenatal insult when revealing typical late sequelae already
mentioned in the neuropathology paragraph or generalized
encephalic malformations and developmental anomalies.
Similarly, signs of brain swelling, cortical highlighting, loss
of gray-white matter differentiation, signal abnormalities in
basal ganglia, and thalami are usually intended to be sugges-
tive of perinatal insult. However, none of these signs is
completely specific, as each one of them has been associated
with the evidence of placental inflammation and no asphyxial
birth event [104]. Not surprisingly even when discussing the
results obtained from large case series, neuroradiologists
agree that imaging findings should be reviewed in the context
of the clinical setting to determine the underlying etiology
and time of onset in HII.
At the end, we should not forget that even in the most
accurate and advanced application, false negative cases of
subsequent neurological defects are still observable at
MRI [105], and this fact limits significantly its overall neg-
ative predictive value. Surely, instead, neuroimaging repre-
sents the only surrogate of a pathological assessment in
nonlethal cases.
4. New Perspectives for an Objective Evaluation
4.1. Limits of the Actually Available State of Art. It is not easy
to delineate a proper scenario from all these evidences,
usually conflicting with each other. The most believable
conclusion should be that there are two apparently incom-
patible points of view.
From one side, clinicians’ scientific societies tend to
assign an intrapartum or at least partum-related etiology
for neonatal brain injury and neurodevelopmental disorders
in a few cases only [106]. According to this, it would be
possible to define it only for contemporary assessment of
acidosis at umbilical cord arterial blood sample, early onset
of moderate-severe encephalopathy, spastic or dyskinetic
neuromotor impairment, and absence of other possible
causes [107]. At the other hand, neuropathological-oriented
reviews still consider the prevalent role of birth asphyxia
and peripartum onset of brain insult. Thus, they consider
the criteria reported as too restrictive and essentially unfit
to describe the real epidemiology.
In order to widen clinical evaluation, a few interesting
diagnostic checklists have been proposed [108, 109]. They
consist of nonweighted lists of indicators, based predomi-
nantly on maternal and gestational clinical history, that
are largely evaluated in literature as singular risk factors
for neurological impairment of childhood. Unfortunately,
this kind of clinical tool is hardly decisive in a judicial setting
because, in the given case, usually more than one factor
coexist, attributable to opposite causation according to
the checklist itself. It is even harder in the case of penal trials
where the judge pretends from the forensic pathologist or
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the medicolegal consultant to answer based on certainty
(or “almost certainty”).
At the state of knowledge, we reviewed by now in this
work that it would be theoretically possible to trust in
neuroimaging to assess if an insult occurred during labor
and delivery or was already established during pregnancy.
However, in the real world, the actual availability of the
needed exams is inadequate to solve most of the cases.
Moreover, expert radiologists in this high specialized and
difficult field is still lacking. Obviously, as we said before,
when survival interval of the newborn is short or a still-
birth occurs and an autopsy is performed, neuropatholog-
ical findings strongly prevail on imaging. Nevertheless, lots
of cases, especially in civil courts, are debated without any
autoptic result. In other circumstances, death might happen
after a considerable lag time since birth so pathological
findings would be nonspecific to time the onset while
MRI scans, if obtained during the first days of life, it would
be more useful.
Anyway, notwithstanding the availability of exams and
observations at both clinical imaging and postmortem
pathology, all the parameters seen are subjective and
operator-dependent. This represents a considerable limit to
the exploitation of similar evidences for the burden of proof
in a given trial setting.
4.2. New Tools for an Evidence-Based Medicolegal
Assessment. Forensic pathology shows rising interest in
implementing immunohistochemistry essays in order to
corroborate qualitative evidences with semiquantitative
parameters. Not surprisingly, then, different immunohisto-
chemical markers have been tested for their predictive value
in timing the onset of neonatal HII. First of all, common
markers for inflammatory responses, such as CD68, CD45,
KP1, and HAM56, react for activated microglia or macro-
phages; more specifically in the nervous tissue, immune
stainings for glial fibrillary acidic protein are commonly used
to highlight reactive astrocytes. These reactions are believed
to be reliable to time the onset of injury at 1 or more days
before the examination, at least; they have a comprehensible
limit in still poor resolution of the lag time, and they are also
nonspecific in relation to the kind of insult.
Specific apoptosis immunohistochemical essays, like
TUNEL (terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate nick end labeling), Bcl-2, and
Bcl-x, have been tested to characterize hypoxic-ischemic
brain lesions, but it was not made in the timing perspective
[110]; the same happened with the VEGF (vascular endothe-
lial growth factor) mapping in hypoxic central nervous tissue.
More recently, instead, Riezzo et al. provided precious
evidences searching for early-induced molecules driven
by hypoxia [111]. They found a well-defined pattern in
chaperonins HSPs and ORP150 (osteogenetic regulatory
protein) over time expression; they concluded that positiv-
ity for both HSP70 and ORP150 is consistently associated
with a lag time from the insult of less than 8 hours, while
HSP90 turns positive only after this time span until about
48 hours. Not surprisingly, HSP70, that had already been
associated with ischemic nervous tissue [112], could be a
protective cellular factor from apoptosis by maintaining
Ca2+ homeostasis [113].
In the future studies, we can hypothesize a growing deep-
ness in molecular mapping of injured brain tissue, not only in
relation to time but also to the type of injury, as we already
see with the application of advanced blotting techniques
[114] and quantitative RT-PCR for extracted RNA [115].
Surely, big efforts will interest microdissection and targeted
miRNA and gene expression analysis.
The counterpart of objective immunohistochemical and
molecular data for the nonautoptical cases could become
soon the serum or cerebrospinal fluid biomarker for neonatal
encephalopathy [116, 117]. At present, clinically used bio-
markers to aid the diagnosis of HIE are quite general cytolytic
ones like creatine kinase isoenzyme (CK-BB) and lactic dehy-
drogenase (LDH). Lots of others are being evaluated in the
experimental setting in consideration of molecular character-
ization of central nervous tissue, by analogy with brain
trauma research [118]. A recent review on potential bio-
marker proposes the implementation of GFAP and the spec-
trin protein breakdown products as reliable serum markers
to assess brain injury. According to other authors, neuronal
protein S-100betha and neuron-specific enolase (NSE)
could be useful to predict outcomes in encephalopathic
babies [119, 120] while the glial to neuronal biomarker ratio
has been proposed as an indicator to differentiate focal and
diffuse injury [121]. Notably, none of these has been studied
for an etiological diagnosis or as a timer [122] but it is reason-
able to think that if they became common in clinical practice,
their real-time correlation with clinical features would be
really useful to time the onset, especially retrospectively.
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